CLOSE

The pressure to create a coronavirus vaccine is increasing by the day, but it takes time to get a safe vaccine on the market.

Today USA

The United States announced Friday that it will pay French pharmaceutical company Sanofi and Britain’s GlaxoSmithKline up to $ 2.1 billion to test and produce 100 million doses of an experimental coronavirus vaccine.

More than half of the money will support clinical developments and trials at first to ensure it is effective and safe. The rest will pay the first 100 million doses, with an option over 500 million more.

Most of the $ 2.1 billion will go to Sanofi, which made the candidacy for the vaccine. GlaxoSmithKline performed a booster that improves the body’s response to this fact.

The agreement is part of Operation Warp Speed, a White House-led initiative to get a vaccine to stop SARS-CoV-2, the virus that causes COVID-19. The Trump administration’s initiative has spent more than $ 8 billion on experimental vaccines that may or may not reach the finish line.

Historical moment: Large-scale trials of possible COVID-19 vaccines begin

Operation warp speed: Officials shun criticism, saying “we are taking every possible step” for the COVID-19 vaccine

Expert panel: The early success of the candidates for the COVID-19 vaccine fuels optimism, but experts warn that “it must be very good”

They are manufactured “at risk” before you have the license. If any of the vaccines are not approved, the accumulated doses will be destroyed.

The companies are collaborating with the U.S. Department of Health and Human Services and the Department of Defense to expand their manufacturing capabilities in the United States.

The Sanofi experimental vaccine uses DNA and an experimental vaccine never released against the SARS virus. Phase 1 and Phase 2 clinical trials of the candidate vaccine will begin in September, said Thomas Triomphe, global head of Sanofi Pasteur, Sanofi’s vaccine wing.

The potential vaccine could begin studies in phase 3, the final phase before licensing, in late 2020. If it is shown to be safe and effective, companies plan to apply for regulatory approval at the first mid-2021.

This is the fourth agreement the federal government has committed to buying doses if companies successfully develop coronavirus vaccines.

CLOSE

Anthony Fauci said Tuesday that the development of a coronavirus vaccine was advancing at a rapid pace. Fauci spoke when President Donald Trump on Tuesday issued a strong defense of the disapproved use of an anti-malarial drug as a treatment. Coronavirus. (July 28)

Domestic AP

Under an agreement reached in May, the British-Swedish firm AstraZeneca would receive $ 1.2 billion for 300 million doses. In July, a $ 1.95 billion deal was announced with U.S.-based Pfizer for 100 million doses. Maryland-based Novavax announced in July that it will receive $ 1.6 billion from the government to fund the development, testing and 100 million doses of its vaccine candidate.

“The vaccine portfolio that is being assembled for Operation Warp Speed ​​increases the chances that we will have at least one safe and effective vaccine as early as the end of this year,” the Secretary of Health and Human Services said. Alex Azar, in a written statement.

The latest agreement has “the potential to provide hundreds of millions of safe and effective doses to the American people,” he said.

Sanofi and GSK made sure they are committed to making the vaccine available globally and that they are building manufacturing capabilities to produce up to a billion doses a year.

The candidate for the DNA-based vaccine is one of two that companies are working on. The other is a messenger RNA vaccine, the same type that Modern develops.

For the second, they plan to begin Phase 1 testing in late 2020 and plan to have a vaccine ready to begin regulatory approval in the second half of 2021, the companies said.

Read or Share this story: https://www.usatoday.com/story/news/2020/07/31/2-1-billion-sanofi-gsk-deal-100-million-coronavirus-vaccine-doses/5554814002/